Inovio Pharmaceuticals is trading at $0.98, up 5.43% pre-market versus its October 28 close of $0.93; the cause of the move remains unclear. - No new company-specific announcement explaining the October 29 move was identified. - The latest major company news remains the October 20 court judgment; collection may be impaired by the defendants’ financial condition. - The FDA’s target action date for INO-3107 is October 30, but available information does not establish that the decision drove the gain.